Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for AEterna Zentaris Inc. (AEZS : NSDQ)
 
 • Company Description   
AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers.

Number of Employees: 17

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.20 Daily Weekly Monthly
20 Day Moving Average: 895,904 shares
Shares Outstanding: 121.40 (millions)
Market Capitalization: $24.64 (millions)
Beta: 1.62
52 Week High: $1.15
52 Week Low: $0.18
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -33.42% -25.01%
12 Week -39.76% -33.77%
Year To Date -42.87% -30.19%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
222 BAY STREET SUITE 3000 PO BOX 53
-
TORONTO,A6 M5K 1E7
CAN
ph: 49-6942-6020
fax: 418-948-9191
aezs@jtcir.com http://www.zentaris.com
 
 • General Corporate Information   
Officers
Klaus Paulini - President and Chief Executive Officer
Egbert, Carolyn - Director; Chair of the Board
Auld, Leslie - Senior Vice President; Chief Financial Officer
Edwards, Peter G. - Director
Gagnon, Gilles - Director

Peer Information
AEterna Zentaris Inc. (CORR.)
AEterna Zentaris Inc. (RSPI)
AEterna Zentaris Inc. (CGXP)
AEterna Zentaris Inc. (BGEN)
AEterna Zentaris Inc. (GTBP)
AEterna Zentaris Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 007975402
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/03/22
Share - Related Items
Shares Outstanding: 121.40
Most Recent Split Date: 11.00 (0.01:1)
Beta: 1.62
Market Capitalization: $24.64 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.03 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.11 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/03/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.46
Price/Cash Flow: -
Price / Sales: 6.71
EPS Growth
vs. Year Ago Period: 0.00%
vs. Previous Quarter: 0.00%
Sales Growth
vs. Year Ago Period: 158.87%
vs. Previous Quarter: 58.68%
ROE
03/31/22 - -16.31
12/31/21 - -13.55
09/30/21 - -13.07
ROA
03/31/22 - -11.49
12/31/21 - -9.69
09/30/21 - -8.94
Current Ratio
03/31/22 - 11.84
12/31/21 - 9.12
09/30/21 - 15.16
Quick Ratio
03/31/22 - 11.79
12/31/21 - 9.11
09/30/21 - 15.14
Operating Margin
03/31/22 - -252.34
12/31/21 - -294.42
09/30/21 - -156.35
Net Margin
03/31/22 - -252.34
12/31/21 - -294.42
09/30/21 - -156.35
Pre-Tax Margin
03/31/22 - -259.39
12/31/21 - -161.16
09/30/21 - -149.94
Book Value
03/31/22 - 0.44
12/31/21 - 0.44
09/30/21 - 0.49
Inventory Turnover
03/31/22 - 1.20
12/31/21 - 1.45
09/30/21 - 30.09
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©